Blood biomarkers of mild traumatic brain injury: State of art |
| |
| Institution: | 1. Biochemistry and molecular biology department, CHU Gabriel-Montpied, Clermont-Ferrand, France;2. ASM Clermont Auvergne, service médical, 63028 Clermont-Ferrand cedex 2, France;3. Service de nutrition clinique, université Clermont Auvergne, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France;4. Service de neurochirurgie, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France;5. Service de médecine du sport, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France;1. Department of Emergency Medicine, Affiliated Hangzhou First People''s Hospital, Zhejiang University School of Medicine, 261 Huansha Road, Hangzhou 310006, China;2. Liangzhu Hospital of Yuhang District of Hangzhou City, 1657 Moganshan Road, 311113 Hangzhou, China;1. Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, Texas, USA;2. Department of Orthopedic Surgery, UT Southwestern Medical Center, Dallas, Texas, USA;1. Service de neurochirurgie, Center for Evaluation and Multidisciplinary Care of Mild Traumatic Brain Injury, Bicêtre University Hospital, Paris, France;2. Service de neurochirurgie, hôpital Beaujon, université de Paris, Assistance publique–Hôpitaux de Paris, 100, avenue du Général-Leclerc, 92110 Clichy, France;1. Emergency & Trauma Centre, The Alfred Hospital, Melbourne, Australia;2. National Trauma Research Institute, The Alfred Hospital, Melbourne, Australia;3. School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia;4. Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Australia;5. Department of Neuroscience, Central Clinical School, Monash University, Australia;6. GLIA Diagnostics, Melbourne, Australia;7. Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne, Melbourne, Australia;8. Monash-Epworth Rehabilitation Research Centre, Epworth Hospital, Melbourne, Australia;9. Department Neurosurgery, Alfred Hospital, Melbourne, Australia;10. Department Surgery, Monash University, Melbourne, Australia |
| |
| Abstract: | BackgroundMild traumatic brain injury (mTBI) is one of the most common causes of emergency department visits around the world. Up to 90% of injuries are classified as mTBI. Cranial computed tomography (CCT) is a standard diagnosis tool to identify intracranial complications in adults with mTBI. Alternatively, children can be admitted for inpatient observation with CCT scans performed only on those with clinical deterioration. The use of blood biomarkers is a supplementary tool for identifying patients at risk of intracerebral lesions who may need imaging.MethodWe realised a bibliographic state of art providing a contemporary clinical and laboratory framework for blood biomarker testing in mTBI management.ResultsThe S100B protein is the only biomarker that can be used today in the clinical routine for management of mTBI with appropriate evidence-based medicine. Due to its excellent negative predictive value, S100B protein is an alternative choice to CCT scanning for mTBI management with considered, consensual and pragmatic use. In this state of art, we propose points to help clinicians and clinical pathologists use serum S100B protein in the clinical routine. A state of art on the different biomarkers (GFAP, UCH-L1, NF H or L], tau, H-FABP, SNTF, NSE, miRNAs, MBP) is also conducted. Some of these other biomarkers, used alone (GFAP, UCH-L1) or in combination (GFAP + H-FABP ± S100B ± IL10) can improve the specificity of S100B.ConclusionUsing a bibliographic state of art, we highlighted the added values of the blood biomarkers for the clinical management of mTBI. |
| |
| Keywords: | mTBI Biomarkers S100B GFAP UCH-L1 H-FABP SNTF NFL NHL MBP NSE miRNA TCL Biomarqueurs S100B GFAP UCH-L1 H-FABP SNTF NFL NHL MBP NSE miRNA |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
